MS-MPSC@EC2608A

MicroPort Expected to Turn Profitable in 2025

MicroPort Expands in Cardiovascular Interventions and Other Business Sectors

MicroPort Sees 119% Return in Past Year but Reports 0.7% Revenue Decline

Citi Reiterates Buy Rating on MicroPort

China Everbright 上调 MicroPort 的净利润预期并维持买入评级

MicroPort Cardiovascular Announces 350% TAVI Procedure Growth and Plans Acquisition

Microport Cardiovascular Announces One-Year Follow-Up Results of AltaValveTM and Completes Financing

MicroPort Medical Technology Deconsolidates Subsidiary

MicroPort Surgical Robot Toumai Secures Over 230 Global Orders

MicroPort Cardiovascular Completes Merger with MicroPort CRM

MicroPort Cardiovascular Flow Tech Acquires MicroPort Cardiac Rhythm Management

MicroPort Cardiovascular Reorganizes Board to Enter Heart Failure Treatment Market

MicroPort Medical Cardiovascular Shareholders Approve Merger with CRM and Heart Rhythm Management

MicroPort Obtained CE Mark Approval for SmartView Connect™

JPMorgan Raises Stake in MicroPort Medical

MicroPort Cardiovascular to Hold Extraordinary Shareholders' Meeting to Review Subsidiary Merger

BofA Securities Reiterates Buy Rating on MicroPort Medical with Raised Target Price

Shanghai MicroPort Medical Technology Co. Reports Growth in Sales and Net Income for Q3 2025

MicroPort passes new governance framework special resolution

MicroPort Coronary Stent System Exceeds 10 Million Units Globally

CCOE

STARCOIN GROUP

ONEFORCE HLDGS

ROYAL DELUXE

STELUX HOLDINGS

TE HEALTHCARE

ASIAPAC FIN INV

WELIFE TECH

DRINDA

TIMELESS

02252

159898

02172

02160

00853

562600

MicroPort Scientific Corporation's affiliate, Endovastec, reported unaudited 2025 revenue of RMB 1.35 billion, marking an 11.96% increase year-on-year. The company achieved a profit of RMB 653.37 million, with a net profit attributable to equity owners of RMB 563.21 million. As of December 31, 2025, total assets reached RMB 4.64 billion, and equity attributable to owners rose to RMB 4.08 billion.

PUBT

MircroPort Medbot-B

China Merchants CSI All Share Medical Apparatus and Instruments ETF

MICROPORT NEURO

MP CARDIOFLOW-B

MICROPORT

ChinaAMC CSI All Share Health Care Devices ETF

MicroPort Affiliate Endovastec Posts 2025 Revenue Growth to RMB1.35 Billion

MicroPort CardioFlow Medtech Corp. has received shareholder approval for a share consolidation, reducing issued shares from approximately 6.37 billion to about 1.27 billion. This consolidation will take effect on 24 February 2026, aiming to enhance trading efficiency and price perception. Existing blue share certificates will remain valid but not for trading after new light-gold certificates are issued. The company will also adjust share options accordingly. The latest analyst rating for the stock (HK:2160) is a Sell with a price target of HK$0.74.

Tip Ranks

MicroPort CardioFlow Wins Shareholder Approval for Share Consolidation Effective 24 February

MicroPort CardioFlow has merged with MicroPort CRM to create a comprehensive platform focused on structural heart, cardiac rhythm management, and heart failure. This merger aims to enhance access to advanced cardiovascular technologies globally. The original content was published by MicroPort Scientific Corporation on February 10, 2026.

Reuters

MicroPort CardioFlow Merges with MicroPort CRM

688351

688016

MICROPORT opened high today at 6.34%, reaching a maximum of 13.95 yuan. It is currently reported at 13.45 yuan, up 7.95%, with a trading volume of 15.7865 million shares, involving a capital of 213 million yuan. The company recently issued a profit warning, expecting to turn a profit in the fiscal year 2025, with a net profit of no less than 20 million USD, compared to a net loss of 268 million USD in the previous year

AASTOCKS

MICROPORT EP

Endovastec

MicroPort rose nearly 8% after issuing a profit warning, expecting to turn a profit last year

MicroPort Scientific (HK:0853) has announced a positive profit alert, expecting a net profit of at least US$20 million for the year ending December 31, 2025, a turnaround from a net loss of approximately US$268 million the previous year. This improvement is driven by 70% revenue growth in its overseas business, enhanced gross margins from cost optimization, reduced operating expenses, and gains from subsidiary disposals. The stock currently holds a Hold rating with a price target of HK$11.00, reflecting a significant operational and financial recovery ahead of full results due by March 2026.

MicroPort Scientific Flags Return to Profit on Overseas Growth and Cost Cuts

MicroPort Scientific Corporation (HKG:853) has delivered a remarkable 119% return to shareholders over the past year, despite a recent 17% drop in share price in the last quarter. The stock surged 8.6% in the past week, adding HK$1.8 billion to its market cap. However, the company reported a 0.7% decline in revenue, raising questions about its long-term growth potential. Insider buying in the past year is a positive sign, but future earnings will be crucial for sustaining shareholder returns. Overall, the short-term gains contrast with a long-term TSR loss of 12% per year over five years.

Simplywall

MicroPort Scientific (HKG:853) delivers shareholders splendid 119% return over 1 year, surging 8.6% in the last week alone

01066

The overseas expansion of innovative drugs and BD transactions have driven the explosive growth of stock prices in the pharmaceutical sector. By 2025, net purchases from southbound funds are expected to reach HKD 1.4 trillion, with the Hong Kong Stock Exchange Healthcare Index increasing by 76% this year. Structural differentiation is evident in the biopharmaceutical sector, with companies possessing First-in-Class or Best-in-Class R&D pipelines being more favored. The medical devices and supplies sector has performed well, with representative companies such as WEIGAO GROUP and MICROPORT seeing increases of 38% and 76% respectively this year

BambooWorks

WEIGAO GROUP

BD transactions and policy dividends resonate, the pharmaceutical sector will have a strong rebound in 2025

A Chinese robot, developed by Shanghai MicroPort MedBot, successfully performed autonomous biliary surgery on a pig, marking a significant advancement in robotic surgery. The MedBot's Neuron AI model, trained on extensive surgical data, executed 88% of the procedure autonomously. While the surgery was supervised by human surgeons, the experiment does not imply safety or efficacy for human applications, as it lacks regulatory approval. Shares of MedBot fell nearly 2% following the announcement. This milestone highlights the growing role of AI in medical technology, alongside developments from other tech giants like Alibaba and Tencent.

南华早报

AI surgery: Chinese robot conducts complex operation on pig without human intervention

MICROPORT announced the termination of the merger with MICROPORT Neuroscience, stating that after appointing an independent non-executive director, the company believes it cannot control MICROPORT Neuroscience according to accounting policies but still maintains significant influence. The termination of the merger is expected to recognize gains from deemed disposal of the subsidiary

MicroPort terminates merger with MicroPort Neuroscience

MicroPort Scientific Corporation has deconsolidated MicroPort NeuroScientific Corporation after appointing an independent non-executive director to its board. This change means MicroPort Scientific no longer controls the target company but retains significant influence. The company will recognize any gain from the disposal of its subsidiary based on the fair value of its equity interest and the net asset value of the target company, pending final audit review.

MicroPort Scientific Deconsolidates NeuroScientific Corporation After Board Changes

MicroPort CardioFlow Reports Strong One-Year AltaValve TMVR Data as Device Advances in Global Trials

MicroPort CardioFlow Reports Strong One-Year AltaValve TMVR Data as Device Advances in Global Trials

MicroPort CardioFlow Medtech Corporation reported a 350% year-on-year increase in TAVI implantations for 2025, expecting over 850 cases. The VitaFlow® series has been introduced in 35 countries, with nearly 1,300 cumulative implantations. The second half of 2025 saw a 170% increase in volume, driven by the expansion of VitaFlow Liberty® post-CE mark approval and growth in emerging markets. The acquisition of MicroPort Cardiac Rhythm Management Limited is anticipated to improve market access in mature markets like Europe.

MicroPort CardioFlow Reports 350% Year-on-Year Increase in TAVI Implantations for 2025

MS-MPSC@EC2608A(23705.HK)

MicroPort Affiliate Endovastec Posts 2025 Revenue Growth to RMB1.35 Billion

MicroPort CardioFlow Wins Shareholder Approval for Share Consolidation Effective 24 February

MicroPort CardioFlow Merges with MicroPort CRM

MicroPort rose nearly 8% after issuing a profit warning, expecting to turn a profit last year

MicroPort Scientific Flags Return to Profit on Overseas Growth and Cost Cuts